晨光生物科技集团股份有限公司 独立董事关于公司2023年半年度相关事项的独立意见 根据《公司法》《证券法》《上市公司独立董事规则》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》等法律法规及《公司章程》的有关规定，作为晨光生物科技 集团股份有限公司（简称"公司"或"晨光生物"）的独立董事，本着谨慎原则， 基于独立判断的立场，现发表独立意见如下： 一、关于公司 2023 年半年度关联交易事项的独立意见 报告期内，公司独立董事根据股东大会审批的标准领取工作津贴，其他董事、 监事、高管根据其在公司担任的运营职务领取薪酬（不领取董事或监事津贴）， 决策程序合规。2023 年上半年公司与关联方发生的关联交易均根据《深圳证券 交易所创业板股票上市规则》《公司章程》等相关规定履行了相关审批程序，交 易金额未超过经审批的关联交易额度，交易的价格按照独立交易原则，参考市场 行情协商确定，不会损害公司及股东利益，不影响公司的独立性。 二、关于公司控股股东及其他关联方占用公司资金、公司对外担保情况的独 立意见 三、关于募集资金 2023 年半年度存放与使用情况的独立意见 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—108 晨光生物科技集团股份有限公司董事会 关于募集资金 2023 年半年度存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等有关要求，公司董事会编制了截至 2023 年 6 月 30 日"关于募集资金 2023 年半年度存放与使用情况的专项报告"。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准晨光生物科技集团股份有限公司公开 发行可转换公司债券的批复》（证监许可[2019]2571 号）核准，同意公司向社会 公开发行面值总额 63,000 万元的可转换公司债券，期限 6 年。本次发行可转换 公司债券的募集资金总额为人民币 63,000 万元，扣除通过募集资金专户支付的 承销、保荐佣金共计人民币 10,698,113.20 元（不含税）后，主承销商中原证券 股份有限公司于 2020 年 6 月 23 日将款项 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—105 晨光生物科技集团股份有限公司 第五届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）监事会于2023年7月 27日以专人送达、邮件方式向全体监事发出第五届监事会第二次会议通知，会议 于2023年8月10日在公司会议室以现场与通讯相结合的方式召开。本次会议由监 事会主席翟艳忠先生主持，应出席会议监事三人，实际出席会议监事三人（监事 王少华以通讯表决方式参加），本次会议召开符合《公司法》《公司章程》等有 关规定。经与会监事研究、讨论，审议通过以下议案： 一、 审议通过了《关于 2023 年半年度报告全文及其摘要的议案》 经审核，监事会认为：公司董事会编制和审核公司 2023 年半年度报告的程 序符合法律、法规、中国证监会和深圳证券交易所等相关规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在虚假记载、误导性陈述或者重大遗 漏。 表决结果：同意三票；反对零票；弃权零票。 表决结果：同意三票；反对零票；弃权零票。 ...

证券代码：300138 证券简称：晨光生物 编号：2023-004 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 投资者关系活动类 别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他 参与单位名称及人 员姓名 参加 2023 年河北辖区上市公司网上集体接待日的投资者 时间 2023 年 5 月 30 日下午 15:00-17:00 地点 全景网"投资者关系互动平台"（https://ir.p5w.net） 上市公司接待人员 1、董事会秘书、财务负责人周静 2、证券事务代表高智超 公司于 2023 年 5 月 30 日通过全景网"投资者关系互 动平台"（https://ir.p5w.net）采用网络远程的方式召开 业绩说明会，公司就投资者在本次说明会中提出的问题进 行了回复，详见全景网本次业绩说明会的交流内容。主要 问题及回复如下： 1、您好，请问公司认为什么时候会扩大中药方面的市 投资者关系活动主 场？ 要内容介绍 您好，中药、保健品是公司第三部发展战略方向，现 阶段主要以研发、投入为主。谢谢关注。 2、建议公司大健康板块可开发含番茄红素和含叶黄素 的矿泉水，或与该领域的龙头比如农夫山泉 ...

证券代码：300138 证券简称：晨光生物 公告编号：2023—078 晨光生物科技集团股份有限公司 关于参加河北辖区上市公司2023年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 晨光生物科技集团股份有限公司（以下简称"公司"）2022年年度报告已于 2023年3月28日公布于巨潮资讯网（http://www.cninfo.com.cn）。为便于广大 投资者更深入全面地了解公司情况、发展战略、经营状况、可持续发展等投资者 所关心的问题，公司将于2023年5月30日（星期二）下午15:00-17:00参加由中国 证监会河北监管局、河北省上市公司协会与深圳市全景网络有限公司联合举办的 "2023年河北辖区上市公司投资者集体接待日活动"。 本次活动将在深圳市全景网络有限公司提供的网上平台采取网络远程的方 式举行，投资者可登录"全景路演"网站（http://rs.p5w.net），或关注微信 公众号：全景财经，或下载全景路演APP,参与本次互动交流。届时，董事会秘书 兼财务负责人周静及证券部人员将在线与广大投资者进行互动交流，欢迎 ...

Financial Performance - The company's revenue for Q1 2023 was ¥1,817,862,277.48, representing a 14.71% increase compared to ¥1,584,746,474.76 in the same period last year[4] - Net profit attributable to shareholders was ¥135,043,557.83, up 26.30% from ¥106,924,931.52 year-on-year[4] - The company's basic earnings per share increased to ¥0.2535, a rise of 26.31% from ¥0.2007 in the same period last year[4] - The company reported a 30.62% increase in income tax expenses, reflecting the rise in profits during the reporting period[15] - Total operating revenue for Q1 2023 reached CNY 1,817,862,277.48, an increase of 14.74% compared to CNY 1,584,746,474.76 in the same period last year[36] - Net profit for Q1 2023 was CNY 139,942,815.94, representing a 30.93% increase from CNY 106,869,101.26 in Q1 2022[37] - Earnings per share (EPS) for Q1 2023 was CNY 0.2535, compared to CNY 0.2007 in the previous year, marking a 26.33% increase[38] Cash Flow and Assets - The net cash flow from operating activities was -¥135,845,984.90, a decrease of 379.81% compared to -¥28,312,350.64 in the previous year[4] - As of March 31, 2023, the company's cash and cash equivalents increased to ¥1,593,604,786.64 from ¥1,146,656,571.64 at the beginning of the year, representing an increase of approximately 39.1%[33] - The total current assets rose to ¥5,651,298,859.32, up from ¥4,926,772,712.74, indicating a growth of about 14.7%[33] - The company's inventory increased to ¥2,487,020,081.00 from ¥2,033,380,620.48, reflecting a rise of approximately 22.3%[33] - The total assets at the end of the reporting period were ¥7,637,338,957.57, an increase of 10.31% from ¥6,923,739,569.28 at the end of the previous year[5] - The total liabilities increased to CNY 4,274,955,745.12 from CNY 3,709,657,856.10, indicating a growth of 15.25% year-over-year[35] - The total equity attributable to shareholders of the parent company rose to CNY 3,310,166,549.84, up from CNY 3,164,817,273.47, reflecting a 4.59% increase[35] Investment and Income - Investment income increased by 628.60% year-on-year, attributed to increased financial management of idle funds[12] - The cash received from investment increased by 2,262,596.50% year-on-year, due to the recovery of principal from financial management and equity transfer payments[16] - The company reported an investment income of CNY 10,596,612.31, significantly higher than CNY 1,455,486.76 in the previous year, showcasing improved investment performance[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,004, with no preferred shareholders[21] - The largest shareholder, Lu Qingguo, holds 18.43% of the shares, amounting to 98,196,051 shares, with 73,647,038 shares pledged[21] - The total number of restricted shares at the beginning of the period was 104,548,148, with 3,553,125 shares released during the period, resulting in a total of 101,033,549 restricted shares at the end of the period[25] Research and Development - Ongoing R&D projects include improving the yield of chili red pigment and optimizing the production process of stevia[29] - The company is actively developing differentiated and customized products to enhance customer solutions and product value[28] - The company completed the development of several new products, including application-specific products and microencapsulated products, aimed at enhancing market competitiveness[30] - The company has made progress in the development of new health food products, including glucosamine calcium tablets, which are expected to enhance market competitiveness[30] - The company is focusing on improving the quality of its products, including the development of new extraction processes for chili peppers, to strengthen its competitive advantage[30] Operational Costs - Operating costs amounted to CNY 1,585,966,370.73, up from CNY 1,369,523,823.31, reflecting a year-over-year increase of 15.75%[37] - Cash paid for purchasing goods and services was 1,974,123,601.80 CNY, compared to 1,743,302,016.66 CNY in the same quarter last year[41] Financing Activities - The net cash flow from financing activities was 393,053,434.99 CNY, a recovery from -33,515,005.76 CNY in the same quarter last year[42] - The company received 754,687,439.90 CNY in cash from borrowings, up from 585,931,000.00 CNY year-over-year[42] - Cash paid for debt repayment was 167,759,305.56 CNY, a decrease from 543,989,960.00 CNY in the previous year[42]

Financial Performance - The company's operating revenue for 2022 was CNY 6,295,872,780.53, representing a 29.18% increase compared to CNY 4,873,610,394.24 in 2021 [24]. - The net profit attributable to shareholders for 2022 was CNY 434,033,194.20, up 23.48% from CNY 351,514,428.78 in 2021 [24]. - The net profit after deducting non-recurring gains and losses was CNY 371,840,318.84, a 30.68% increase from CNY 284,546,967.11 in 2021 [24]. - The net cash flow from operating activities reached CNY 734,807,406.57, a significant increase of 1,049.93% compared to CNY 63,899,957.93 in 2021 [24]. - The total assets at the end of 2022 were CNY 6,923,739,569.28, reflecting a 16.26% increase from CNY 5,955,165,411.81 at the end of 2021 [24]. - The weighted average return on equity for 2022 was 14.60%, an increase from 13.58% in 2021 [24]. - The company reported a total procurement amount of CNY 5,023.05 million for raw materials, with over 30% sourced from cooperatives or farmers [72]. - The company's total operating costs for 2022 were CNY 5,418.15 million, reflecting a year-on-year increase of 30.42% [73]. - The gross profit margin for the natural plant extraction industry was 13.94%, with a slight decrease of 0.81% compared to the previous year [108]. Market Position and Growth Potential - The global market size for plant extracts is expected to reach $59.4 billion by 2025 [35]. - The market for compound seasonings in China grew from 43.2 billion yuan in 2011 to 144 billion yuan in 2020, with a CAGR of 14.31% [42]. - The market size for hot pot seasoning increased from 15.6 billion yuan in 2011 to 56 billion yuan in 2020, with a CAGR of 15.28% [42]. - The penetration rate of pepper extract in the catering industry is currently less than 2%, indicating significant growth potential [44]. - The global market for natural food colorants is projected to reach $2.5 billion by 2025 [40]. - The number of diabetes patients globally reached 537 million in 2021, with 141 million in China, driving demand for natural sweeteners [45]. - The compound seasoning market in China is expected to continue its rapid growth, driven by rising living standards and consumption upgrades [42]. Research and Development - The company has a robust R&D team of over 100 people, focusing on process technology improvement and new product development [51]. - The company has established strong partnerships with universities and research institutions to enhance its R&D capabilities [79]. - The company has built a world-class R&D platform, including a provincial engineering technology research center and a national enterprise technology center [81]. - The company has applied for 456 patents, with 332 granted, and published 228 papers, showcasing its strong focus on research and innovation [80]. - Research and development expenses rose by 36.11% to ¥129,028,765.28, driven by increased investment in process upgrades and project development [119]. - The company is actively developing new technologies and products, including the production of chicory powder and the development of anti-adhesion products, to diversify its product offerings [122]. Product Development and Innovation - The company aims to develop ten products that rank first or among the top in the world, leveraging its R&D and industrial production capabilities [37]. - The company has achieved a significant increase in the market share of chili red pigment from less than 2% to over 80% in the international market [51]. - The company has completed the development of various new products, including microencapsulated products and multi-vitamin tablets, which are expected to enhance market competitiveness [123]. - The company is conducting application research on marigold comprehensive utilization, aiming for large-scale production to meet market demand [121]. - The company is preparing to conduct pilot tests for the water milk thistle extract project, aiming to meet market demand through optimized production processes [121]. Risk Management - The company has not identified any significant risks that could adversely affect its operations in the next reporting period [4]. - The company faces risks from raw material supply and price fluctuations, which significantly impact operating performance due to high raw material cost proportions [57]. - The company adopts a cost-plus pricing strategy to mitigate product price volatility risks, ensuring stable profit margins [57]. - The company has implemented strict risk control measures for hedging activities, including adherence to relevant laws and regulations [144]. Governance and Compliance - The company established a governance structure based on the general meeting of shareholders, board of directors, supervisory board, and management team, ensuring effective decision-making and supervision [179]. - The company’s governance practices comply with legal regulations and the requirements set by the China Securities Regulatory Commission [179]. - The company respects and protects the legitimate rights and interests of stakeholders, emphasizing social responsibility and communication with various parties [185]. - The company adheres to strict information disclosure practices, ensuring timely and accurate information is available to all shareholders through multiple channels [186]. Sustainability and Environmental Commitment - The company is committed to environmental protection and has invested in strict monitoring systems to comply with increasing regulatory standards [60]. - The company is committed to sustainable and healthy development through a scientifically rational product hierarchy, which is a core driver of its performance [52]. - The company has established raw material bases in Xinjiang, Yunnan, and India, and is currently trial planting in Zambia to ensure stable supply of quality raw materials [56]. Strategic Goals and Future Plans - The company aims to build a global natural extract industry base, emphasizing the importance of global resource allocation to achieve this goal [4]. - The company plans to enhance its core competitive advantages and steadily improve operational performance by expanding its marketing team and focusing on user needs in product development [160]. - The company intends to optimize production processes and expand capacity for products like turmeric extract and rosemary extract to create new economic growth points [162]. - The company aims to establish a robust information analysis model to accurately assess market trends and supply-demand relationships [161].

证券代码：300138 证券简称：晨光生物 公告编号：2023—042 晨光生物科技集团股份有限公司 关于举行 2022 年度网上业绩说明会的公告 2023 年 3 月 28 日 为便于广大投资者更深入全面了解公司情况，公司将于 2023 年 4 月 7 日（星 期五）15:00—17:00 在全景网举办 2022 年度业绩说明会。 本次业绩说明会将采用网络远程方式举行，投资者可登陆全景网"投资者关 系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。出席本次说明 会的人员有：公司董事长兼总经理卢庆国先生，董事、财务负责人、董事会秘书 周静女士，独立董事王淑红女士，保荐代表人封江涛先生。 为增进投资者对公司的了解和认同，提升公司治理水平，现就公司 2022 年 度网上业绩说明会提前向投资者征集相关问题、意见或建议，欢迎广大投资者于 2023 年 4 月 5 日 17：00 前，将您关心或关注的问题通过电子邮件的形式发送至 公司邮箱 cgsw@cn-cg.com，公司将在本次业绩说明会上对投资者普遍关注的问 题进行回答。 特此公告 晨光生物科技集团股份有限公司 董事会 本公司及董事会全体成 ...

证券代码：300138 证券简称：晨光生物 编号：2014－001 晨光生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------|------------------------------------------------------| | | | | | | √特定对象调研 | □分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | | √现场参观 | □一对一沟通 | | | □其他 | | | | | | | 参与单位名称及人员 姓名 | 长城证券王建虎 | | | 时间 | 2014 年 12 月 02 日 | | | 地点 | 河北省邯郸市曲周县晨光路 | 1 号 | | 上市公司接待人员 | 周静、高智超、闫仕静 | | | | 1、 润不是很高，原因是什么？ | 棉籽产品收入占公司总体收入一半的比例，但利 | | | 棉籽产出品主要有，（ | 1 ）棉籽蛋白，销售给大的饲料 ...

证券代码：300138 证券简称：晨光生物 编号：2016－001 | --- | --- | --- | |-------------------------|-------------------------------|---------------------------------------------------------------------------------------------| | | | | | | √特定对象调研 | □分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | | □新闻发布会 □路演活动 | | | √现场参观 | □一对一沟通 | | 参与单位名称及人员 姓名 | □其他 | 东吴证券丁一、盛运德诚雷晓光、长江证券董思远、招商 证券李重阳、阳光资管杨赫尘、国寿安保李丹 | | 时间 | 2016 年 01 月 25 日 | | | 地点 | 河北省邯郸市曲周县城晨光路 | 1 号 | | 上市公司接待人员 | 工作人员 | 董事长兼总经理卢庆国、董秘兼财务负责人周静、证券部 | | | 1 | 、到访人员观看公司宣传片、参观 ...